Markets:

Overview

News

Currencies

International

Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

31.60 +1.06 (+3.47%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? ↗

June 03, 2024

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of...

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

Nvidia Again Boosts Nasdaq To Record Highs ↗

May 28, 2024

The Nasdaq Composite Index is extending Friday's record highs, with help from Nvidia, which is up 5% at last glance and marking its own all-time highs.

Via Talk Markets

Topics Stocks

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗

May 28, 2024

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Via Benzinga

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Earnings Preview: Agios Pharmaceuticals ↗

February 14, 2024

Via Benzinga

RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know ↗

June 27, 2023

Via Benzinga

Agios Pharmaceuticals's Return On Capital Employed Overview ↗

May 15, 2023

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

May 28, 2024

Via Benzinga

Agios Pharmaceuticals's Return On Capital Employed Insights ↗

February 24, 2023

Via Benzinga

Agios Pharmaceuticals's Return On Capital Employed Overview ↗

November 17, 2022

Via Benzinga

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗

May 28, 2024

The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 28, 2024

Via Benzinga

Attention Biotech Investors - Stocks To Watch ↗

May 16, 2024

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,...

Via Benzinga

AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 02, 2024

AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

The 3 Best Biotech Stocks to Buy Now: Q2 Edition ↗

April 16, 2024

Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.

Via InvestorPlace

Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗

February 23, 2024

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

Via Investor's Business Daily

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today? ↗

January 03, 2024

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary

Via Benzinga

Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug ↗

January 03, 2024

The company is working on an oral treatment for alpha and beta thalassemia.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 03, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 03, 2024

It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!

Via InvestorPlace

Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat ↗

June 26, 2023

Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its

Via Benzinga

Why Shares of Schrödinger Rose This Week ↗

June 16, 2023

Interest in the company's AI platform continues to drive the stock.

Via The Motley Fool

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

7 Biotech Stocks That Could Be the Next Big Thing ↗

March 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

December 24, 2022

The attraction of all three biotech stocks is their potential.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 ↗

November 17, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.